Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

By afschroeder • July 15, 2025

Wang CJ, Bang A, Chowdhury S, Leslie KS, Lang UE, Shimoda M, Henrich TJ, Hoh R, Deeks SG, Wang C, Deitchman AN, Couey P, Maurer T. Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma. JCO Oncol Adv. 2025 Jul 7;2(1):e2400098. doi: 10.1200/OA-24-00098. PMID: 40655531; PMCID: PMC12244976.

Tags: Dermatology, Publications, Resident

Moyamoya disease presenting as galactorrhea

Noveir SD, Agrawal N. Moyamoya disease presenting as galactorrhea. JCEM Case Rep. 2026 Oct 13;4(11):luag296. doi: 10.1210/jcemcr/luag296. PMID: 42871260; PMCID: PMC13658269.

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns

Park I, Bayrouti A, MacIntyre D, Le V, Nguyen KB. Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns. Dermatol[...]

Closing the Gap: The Ethics of Non-Physician Delegation in Mohs Reconstruction

Li R, Ramirez Y, Stone L, Klufas T, Zhou AE, Tucci C, Beynet DP, Lo Sicco K, Grant-Kels JM. Closing the Gap: The Ethics of[...]